CAUTREELS WERNER 4

What Happened
Cautreels Werner, a director of Traws Pharma, was granted a derivative award on March 8, 2026, covering 31,258 shares. The Form 4 lists the acquisition price as $0.00 and a total reported value of $0 — this reflects an options/award grant rather than a cash purchase or sale.

Key Details

• Transaction date: 2026-03-08 (reported on Form 4 filed 2026-03-10 — appears timely).
• Transaction type: Award/Grant (derivative) of 31,258 shares; reported price $0.00; total $0.
• Vesting: Footnote states these are stock options granted under the Issuer’s 2021 Incentive Compensation Plan; they vest 100% on the first anniversary of the grant.
• Grantor/approver: Award made by the issuer’s compensation committee (comprised of independent directors).
• Shares owned after transaction: Not disclosed in the provided filing.

Context
This was an equity compensation award (options), not an open-market purchase or sale. Such awards are common for directors and do not indicate an immediate cash outlay or immediate sale of shares; vesting means the right to acquire shares is deferred (100% vests after one year). For retail investors, awards show how insiders are being compensated but are less directly informative about immediate insider buying or selling.